Cargando…

Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei

BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei (PMP) is associated with excessive bleeding and acquired fibrinogen deficiency. Maintaining plasma fibrinogen may support hemostasis. OBJECTIVES: To compare hemostatic efficacy and safet...

Descripción completa

Detalles Bibliográficos
Autores principales: Roy, Ashok, Stanford, Sophia, Nunn, Sean, Alves, Sue, Sargant, Nigel, Rangarajan, Savita, Smith, Emily Arbuthnot, Bell, John, Dayal, Sanjeev, Cecil, Tom, Tzivanakis, Alexios, Kruzhkova, Irina, Solomon, Cristina, Knaub, Sigurd, Moran, Brendan, Mohamed, Faheez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027898/
https://www.ncbi.nlm.nih.gov/pubmed/31654548
http://dx.doi.org/10.1111/jth.14665
_version_ 1783498929479876608
author Roy, Ashok
Stanford, Sophia
Nunn, Sean
Alves, Sue
Sargant, Nigel
Rangarajan, Savita
Smith, Emily Arbuthnot
Bell, John
Dayal, Sanjeev
Cecil, Tom
Tzivanakis, Alexios
Kruzhkova, Irina
Solomon, Cristina
Knaub, Sigurd
Moran, Brendan
Mohamed, Faheez
author_facet Roy, Ashok
Stanford, Sophia
Nunn, Sean
Alves, Sue
Sargant, Nigel
Rangarajan, Savita
Smith, Emily Arbuthnot
Bell, John
Dayal, Sanjeev
Cecil, Tom
Tzivanakis, Alexios
Kruzhkova, Irina
Solomon, Cristina
Knaub, Sigurd
Moran, Brendan
Mohamed, Faheez
author_sort Roy, Ashok
collection PubMed
description BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei (PMP) is associated with excessive bleeding and acquired fibrinogen deficiency. Maintaining plasma fibrinogen may support hemostasis. OBJECTIVES: To compare hemostatic efficacy and safety of human fibrinogen concentrate (HFC) vs cryoprecipitate as fibrinogen sources for bleeding patients with acquired fibrinogen deficiency undergoing PMP CRS. METHODS: FORMA‐05 was an off‐label single‐center, prospective, randomized, controlled phase 2 study. Patients undergoing PMP surgery with predicted intraoperative blood loss ≥2 L received human fibrinogen concentrate (HFC; 4 g) or cryoprecipitate (two pools of 5 units, containing approximately 4.0‐4.6 g fibrinogen), repeated as needed. The primary endpoint was a composite of intraoperative and postoperative efficacy, graded using objective 4‐point scales and adjudicated by an independent committee. RESULTS: One hundred percent of patients receiving HFC (95% confidence interval: 83.9‐100.0, n = 21) or cryoprecipitate (84.6‐100.0, n = 22) achieved hemostatic success. HFC demonstrated noninferior efficacy (P = .0095; post hoc) and arrived in the operating room 46 minutes faster. There were significantly greater mean increases with HFC vs cryoprecipitate in plasma fibrinogen (0.78 vs 0.35 g/L; P < .0001) and FIBTEM A20 (3.33 vs 0.93 mm; P = .003). Factor XIII, factor VIII, and von Willebrand factor activity were maintained throughout surgery. Only red blood cells were transfused intraoperatively (median units: HFC group, 1.0; cryoprecipitate group, 0.5). Thromboembolic events were detected with cryoprecipitate only. Safety was otherwise comparable between groups. CONCLUSIONS: Human fibrinogen concentrate was hemostatically efficacious in patients undergoing major abdominal PMP surgery, with a favorable safety profile. These results are relevant to other surgical settings where bleeding and acquired fibrinogen deficiency occur.
format Online
Article
Text
id pubmed-7027898
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-70278982020-02-24 Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei Roy, Ashok Stanford, Sophia Nunn, Sean Alves, Sue Sargant, Nigel Rangarajan, Savita Smith, Emily Arbuthnot Bell, John Dayal, Sanjeev Cecil, Tom Tzivanakis, Alexios Kruzhkova, Irina Solomon, Cristina Knaub, Sigurd Moran, Brendan Mohamed, Faheez J Thromb Haemost HAEMOSTASIS BACKGROUND: Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei (PMP) is associated with excessive bleeding and acquired fibrinogen deficiency. Maintaining plasma fibrinogen may support hemostasis. OBJECTIVES: To compare hemostatic efficacy and safety of human fibrinogen concentrate (HFC) vs cryoprecipitate as fibrinogen sources for bleeding patients with acquired fibrinogen deficiency undergoing PMP CRS. METHODS: FORMA‐05 was an off‐label single‐center, prospective, randomized, controlled phase 2 study. Patients undergoing PMP surgery with predicted intraoperative blood loss ≥2 L received human fibrinogen concentrate (HFC; 4 g) or cryoprecipitate (two pools of 5 units, containing approximately 4.0‐4.6 g fibrinogen), repeated as needed. The primary endpoint was a composite of intraoperative and postoperative efficacy, graded using objective 4‐point scales and adjudicated by an independent committee. RESULTS: One hundred percent of patients receiving HFC (95% confidence interval: 83.9‐100.0, n = 21) or cryoprecipitate (84.6‐100.0, n = 22) achieved hemostatic success. HFC demonstrated noninferior efficacy (P = .0095; post hoc) and arrived in the operating room 46 minutes faster. There were significantly greater mean increases with HFC vs cryoprecipitate in plasma fibrinogen (0.78 vs 0.35 g/L; P < .0001) and FIBTEM A20 (3.33 vs 0.93 mm; P = .003). Factor XIII, factor VIII, and von Willebrand factor activity were maintained throughout surgery. Only red blood cells were transfused intraoperatively (median units: HFC group, 1.0; cryoprecipitate group, 0.5). Thromboembolic events were detected with cryoprecipitate only. Safety was otherwise comparable between groups. CONCLUSIONS: Human fibrinogen concentrate was hemostatically efficacious in patients undergoing major abdominal PMP surgery, with a favorable safety profile. These results are relevant to other surgical settings where bleeding and acquired fibrinogen deficiency occur. John Wiley and Sons Inc. 2019-11-26 2020-02 /pmc/articles/PMC7027898/ /pubmed/31654548 http://dx.doi.org/10.1111/jth.14665 Text en © 2019 Octapharma. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on Thrombosis and Haemostasis This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle HAEMOSTASIS
Roy, Ashok
Stanford, Sophia
Nunn, Sean
Alves, Sue
Sargant, Nigel
Rangarajan, Savita
Smith, Emily Arbuthnot
Bell, John
Dayal, Sanjeev
Cecil, Tom
Tzivanakis, Alexios
Kruzhkova, Irina
Solomon, Cristina
Knaub, Sigurd
Moran, Brendan
Mohamed, Faheez
Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
title Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
title_full Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
title_fullStr Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
title_full_unstemmed Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
title_short Efficacy of fibrinogen concentrate in major abdominal surgery – A prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
title_sort efficacy of fibrinogen concentrate in major abdominal surgery – a prospective, randomized, controlled study in cytoreductive surgery for pseudomyxoma peritonei
topic HAEMOSTASIS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7027898/
https://www.ncbi.nlm.nih.gov/pubmed/31654548
http://dx.doi.org/10.1111/jth.14665
work_keys_str_mv AT royashok efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT stanfordsophia efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT nunnsean efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT alvessue efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT sargantnigel efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT rangarajansavita efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT smithemilyarbuthnot efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT belljohn efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT dayalsanjeev efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT ceciltom efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT tzivanakisalexios efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT kruzhkovairina efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT solomoncristina efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT knaubsigurd efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT moranbrendan efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei
AT mohamedfaheez efficacyoffibrinogenconcentrateinmajorabdominalsurgeryaprospectiverandomizedcontrolledstudyincytoreductivesurgeryforpseudomyxomaperitonei